| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 05/06/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 05/05/2022 | 1338.33% | HC Wainwright & Co. | $5 → $4 | Maintains | Buy |
| 09/21/2021 | 3136.25% | HC Wainwright & Co. | $10 → $9 | Maintains | Buy |
| 08/05/2021 | 3495.83% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 05/05/2021 | 4214.99% | HC Wainwright & Co. | $13 → $12 | Maintains | Buy |
| 11/06/2020 | 978.75% | SVB Leerink | $4 → $3 | Maintains | Underperform |
| 11/06/2020 | 5293.74% | HC Wainwright & Co. | $23 → $15 | Maintains | Buy |
| 05/22/2020 | 10327.9% | HC Wainwright & Co. | $33 → $29 | Reiterates | → Buy |
| 05/20/2020 | 1338.33% | SVB Leerink | $5 → $4 | Maintains | Underperform |
| 05/18/2020 | 11766.24% | HC Wainwright & Co. | $29 → $33 | Maintains | Buy |
| 05/06/2020 | 10327.9% | HC Wainwright & Co. | $27 → $29 | Reiterates | → Buy |
| 04/27/2020 | 1697.91% | SVB Leerink | → $5 | Downgrades | Market Perform → Underperform |
| 04/09/2020 | 2057.5% | B of A Securities | → $6 | Downgrades | Neutral → Underperform |
| 01/23/2020 | 3495.83% | B of A Securities | $7 → $10 | Maintains | Neutral |
| 11/19/2019 | 2776.66% | Evercore ISI Group | → $8 | Downgrades | Outperform → In-Line |
| 10/08/2019 | 978.75% | Goldman Sachs | $13 → $3 | Maintains | Sell |
| 09/24/2019 | — | SVB Leerink | Downgrades | Outperform → Market Perform | |
| 08/13/2019 | 2417.08% | B of A Securities | $13 → $7 | Downgrades | Buy → Neutral |
| 08/02/2019 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 05/29/2019 | 5293.74% | Goldman Sachs | $17 → $15 | Downgrades | Neutral → Sell |
| 02/13/2019 | 14283.32% | HC Wainwright & Co. | → $40 | Initiates Coverage On | → Buy |
| 10/31/2018 | 14283.32% | Barclays | $58 → $40 | Maintains | Overweight |
| 10/31/2018 | 5653.33% | JP Morgan | $71 → $16 | Downgrades | Overweight → Neutral |
| 09/25/2018 | 10687.49% | Leerink Swann | → $30 | Initiates Coverage On | → Market Perform |
| 02/27/2018 | 30464.55% | Barclays | $105 → $85 | Maintains | Overweight |
| 02/27/2018 | 39454.12% | Stifel | $125 → $110 | Maintains | Buy |
| 02/22/2018 | — | Evercore ISI Group | Upgrades | In-Line → Outperform | |
| 02/22/2018 | — | RBC Capital | Upgrades | Sector Perform → Outperform |
What is the target price for Clovis Oncology (CLVS)?
The latest price target for Clovis Oncology (NASDAQ: CLVS) was reported by JP Morgan on November 10, 2022. The analyst firm set a price target for $0.00 expecting CLVS to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Clovis Oncology (CLVS)?
The latest analyst rating for Clovis Oncology (NASDAQ: CLVS) was provided by JP Morgan, and Clovis Oncology downgraded their underweight rating.
When is the next analyst rating going to be posted or updated for Clovis Oncology (CLVS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clovis Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clovis Oncology was filed on November 10, 2022 so you should expect the next rating to be made available sometime around November 10, 2023.
Is the Analyst Rating Clovis Oncology (CLVS) correct?
While ratings are subjective and will change, the latest Clovis Oncology (CLVS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Clovis Oncology (CLVS) is trading at is $0.28, which is out of the analyst's predicted range.